Who are CEP-10953 (Armodafinil)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): cognitive function, modafinil (M1, M2, M4), DOCETAXEL(XRP6976) + MODAFINIL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cep-10953-armodafinil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CEP-10953 (Armodafinil) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CEP-10953 (Armodafinil) (CEP-10953 (Armodafinil)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Wakefulness-promoting agent. Area: Neurology / Sleep Medicine.

phase 3 Wakefulness-promoting agent Dopamine transporter (DAT) Neurology / Sleep Medicine Small molecule Live · refreshed every 30 min

Target snapshot

CEP-10953 (Armodafinil) (CEP-10953 (Armodafinil)) — Cephalon. Armodafinil promotes wakefulness by increasing dopamine levels in the brain, likely through dopamine reuptake inhibition and other monoaminergic pathways.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CEP-10953 (Armodafinil) TARGET	CEP-10953 (Armodafinil)	Cephalon	phase 3	Wakefulness-promoting agent	Dopamine transporter (DAT)
cognitive function	cognitive function	Huazhong University of Science and Technology	marketed	wakefulness-promoting agent
modafinil (M1, M2, M4)	modafinil (M1, M2, M4)	University of California, Los Angeles	marketed	Eugeroic (wakefulness-promoting agent)	Dopamine transporter (DAT); norepinephrine transporter (NET); orexin system modulation
DOCETAXEL(XRP6976) + MODAFINIL	DOCETAXEL(XRP6976) + MODAFINIL	Sanofi	phase 3	Taxane chemotherapy + wakefulness-promoting agent combination	β-tubulin (docetaxel); dopamine/norepinephrine/histamine systems (modafinil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Wakefulness-promoting agent class)

Cephalon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CEP-10953 (Armodafinil) — Competitive Intelligence Brief. https://druglandscape.com/ci/cep-10953-armodafinil. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab